Drug intelligence / Profile preview

Pediococcus pentosaceus M6

Development stage: Preclinical
Lead developer: Inner Mongolia Agricultural University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Pediococcus pentosaceus M6 is a probiotic bacterial strain isolated from equines that is being investigated for its therapeutic potential in treating colitis. [3] The strain itself is the active ingredient, a live lactic acid bacterium. [1, 2] Research published in 2025 demonstrated that this strain can alleviate DSS-induced colitis in mice by reducing weight loss and inflammation. [1, 2, 8] The strain exhibits good biological characteristics including acid tolerance, bile salt tolerance, and antibacterial effects against pathogens like Escherichia coli, Salmonella, and Staphylococcus aureus. [1, 2, 3] While no specific company is mentioned, the research appears to be conducted by academic institutions such as the Inner Mongolia Agricultural University and the Inner Mongolia Academy of Agricultural & Animal Husbandry Sciences. [1] No brand name has been assigned to this research compound.

Beyond the preview

Go deeper on Pediococcus pentosaceus M6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pediococcus pentosaceus M6.

Explore the full profile